ADAG $1.69 (-5.34%) Quote details

stock

Adagene Inc

NASDAQ | ADAG

1.69

USD

-0.095 (-5.34%)

AT CLOSE (AS OF Mar 21, 2025)

$108M

MARKET CAP

-

P/E Ratio

-0.72

EPS

$3.6

52 Week High

$1.6

52 Week Low

LIFE SCIENCES

Sector

ADAG Chart

ADAG Technicals

Tags:

ADAG Earnings

Yearly Income Statement (As of Dec 31, 2023)

Field Value (USD)
Gross Profit $18M
Total Revenue $18M
Cost Of Revenue -
Costof Goods And Services Sold -
Operating Income -$24M
Selling General And Administrative $8.7M
Research And Development $37M
Operating Expenses $42M
Investment Income Net -
Net Interest Income $3.2M
Interest Income $4.3M
Interest Expense $1.1M
Non Interest Income -
Other Non Operating Income -
Depreciation -
Depreciation And Amortization $1.2M
Income Before Tax -$17M
Income Tax Expense $1.7M
Interest And Debt Expense -
Net Income From Continuing Operations -$19M
Comprehensive Income Net Of Tax -
Ebit -$16M
Ebitda -$15M
Net Income -$19M

Revenue & Profitability

Earnings Performance

ADAG Financials

yearly Balance Sheet (As of Dec 31, 2023)

Field Value (USD)
Total Assets $116M
Total Current Assets $113M
Cash And Cash Equivalents At Carrying Value $110M
Cash And Short Term Investments $110M
Inventory -
Current Net Receivables -
Total Non Current Assets $2.3M
Property Plant Equipment -
Accumulated Depreciation Amortization Ppe -
Intangible Assets -
Intangible Assets Excluding Goodwill -
Goodwill -
Investments -
Long Term Investments -
Short Term Investments -
Other Current Assets $3.3M
Other Non Current Assets -
Total Liabilities $45M
Total Current Liabilities $31M
Current Accounts Payable -
Deferred Revenue -
Current Debt -
Short Term Debt $8.6M
Total Non Current Liabilities $14M
Capital Lease Obligations $370K
Long Term Debt $14M
Current Long Term Debt $8.4M
Long Term Debt Noncurrent -
Short Long Term Debt Total $22M
Other Current Liabilities $20M
Other Non Current Liabilities -
Total Shareholder Equity $71M
Treasury Stock -
Retained Earnings -$278M
Common Stock $5.5K
Common Stock Shares Outstanding $44M

yearly Cash Flow (As of Dec 31, 2023)

Field Value (USD)
Operating Cashflow -$28M
Payments For Operating Activities -
Proceeds From Operating Activities -
Change In Operating Liabilities -
Change In Operating Assets -
Depreciation Depletion And Amortization $1.2M
Capital Expenditures $85K
Change In Receivables -
Change In Inventory -
Profit Loss -
Cashflow From Investment -
Cashflow From Financing -$5.4M
Proceeds From Repayments Of Short Term Debt -
Payments For Repurchase Of Common Stock -
Payments For Repurchase Of Equity -
Payments For Repurchase Of Preferred Stock -
Dividend Payout -
Dividend Payout Common Stock -
Dividend Payout Preferred Stock -
Proceeds From Issuance Of Common Stock -
Proceeds From Issuance Of Long Term Debt And Capital Securities Net -
Proceeds From Issuance Of Preferred Stock -
Proceeds From Repurchase Of Equity $0
Proceeds From Sale Of Treasury Stock -
Change In Cash And Cash Equivalents -
Change In Exchange Rate -
Net Income -$19M

yearly Income Statement (As of Dec 31, 2023)

Field Value (USD)
Gross Profit $18M
Total Revenue $18M
Cost Of Revenue -
Costof Goods And Services Sold -
Operating Income -$24M
Selling General And Administrative $8.7M
Research And Development $37M
Operating Expenses $42M
Investment Income Net -
Net Interest Income $3.2M
Interest Income $4.3M
Interest Expense $1.1M
Non Interest Income -
Other Non Operating Income -
Depreciation -
Depreciation And Amortization $1.2M
Income Before Tax -$17M
Income Tax Expense $1.7M
Interest And Debt Expense -
Net Income From Continuing Operations -$19M
Comprehensive Income Net Of Tax -
Ebit -$16M
Ebitda -$15M
Net Income -$19M

ADAG News

ADAG Profile

Adagene Inc Profile

Sector: LIFE SCIENCES

Industry: PHARMACEUTICAL PREPARATIONS

Adagene Inc., a clinical-stage biopharmaceutical company, is dedicated to the research, development, and production of monoclonal antibody drugs for cancer. The company is headquartered in Suzhou, China.


Quotes and other market data may be delayed by 15 minutes or more. Financial data is provided by financial exchanges and other content providers and may be delayed as specified by financial exchanges or other data providers. AfterPullback does not verify any data and disclaims any obligation to do so. The information contained on this website is not intended as, and shall not be understood as, financial advice. The website does not operated by attorney, accountant or financial advisor and the information contained on this website is not a substitute for financial advice from a professional who is aware of the facts and circumstances of your individual situation. Nothing available on or through this website should be understood as a recommendation that you should not consult with a financial professional to address your particular information.